PMID: 8950493Sep 1, 1996Paper

Intracoronary recombinant tissue-type plasminogen activator (rt-PA)

Coronary Artery Disease
A J Tiefenbrunn

Abstract

Intracoronary rt-PA has been used to treat patients with acute myocardial infarction primarily, after failure of intravenous thrombolytic therapy, and when angioplasty has not been technically possible. It has also been used to treat thrombotic closure complicating angioplasty, to treat nonocclusive thrombosis observed during angioplasty, and to pretreat patients with nonacute total occlusions before angioplasty. Intracoronary administration has the potential of providing high local concentrations for a given dose level and may allow lower total doses for the same degree of efficacy. More controlled data are needed on appropriate patient selection, angiographic and clinical endpoints, dose level and regimen, and comparable efficacy of rt-PA and other thrombolytic agents. However, the use of intracoronary rt-PA should be considered when intracoronary thrombus is evident and this route of administration is available.

Citations

Oct 13, 1998·Journal of the American College of Cardiology·S PislaruF Van de Werf
Oct 26, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Ting-Ting HongBenedict R Lucchesi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.